Ustekinumab (Stelara) and Ketamine Therapy | Tovani Health
Stelara (Ustekinumab) — IL-12/23 monoclonal antibody (psoriasis, Crohn's, ulcerative colitis)
Verdict at Tovani Health
Fully compatible with KAP.
Ustekinumab and ketamine have no clinically significant interaction. Same biologic class compatibility as the TNF-α inhibitors — no CYP, no small-molecule interaction surface.
If you take Stelara regularly and are considering at-home ketamine therapy, the combination is generally safe at therapeutic doses. This page covers the brief pharmacologic context and what we do at intake.
How Stelara interacts with ketamine
Ustekinumab is a fully human IgG1 mAb targeting the p40 subunit shared by IL-12 and IL-23. Subcutaneous loading then maintenance every 8-12 weeks.
What we do at intake
Continue as scheduled.
Bottom line
Ustekinumab and ketamine have no clinically significant interaction. Same biologic class compatibility as the TNF-α inhibitors — no CYP, no small-molecule interaction surface.
Ready to find out if at-home ketamine fits your situation?
We’ll note that you’re on Stelara (Ustekinumab) at intake. The eligibility check takes 5 minutes and gives you an honest answer about whether at-home ketamine fits your specific situation.
FL and NJ residents only. Benjamin Soffer, DO — Tovani Health.
Clinically reviewed
Reviewed by Benjamin Soffer, DO on May 19, 2026. Dr. Soffer is a board-certified physician (American Board of Internal Medicine) licensed in Florida and New Jersey, prescribing at-home ketamine therapy through Tovani Health.
This page is general information about how this medication interacts with at-home ketamine therapy at Tovani Health. It is not a substitute for medical advice from your prescribing physician about your specific situation. Always discuss medication changes with the doctor who prescribed them.